Testosterone undecanoate compositions
The present disclosure is drawn to pharmaceutical compositions and oral dosage forms containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the oral dosage form can include a therapeutically effective amount of testosterone undecanoate and a pharmaceutically acceptable carrier. The dosage form can be formulated such that, when measured using a USP Type II apparatus in 1000 mL of 8 wt % Triton X-100 in water at 37° C. and 100 rpm, the oral dosage form releases at least 20% more testosterone undecanoate after the first 120 minutes than an equivalent dose testosterone undecanoate containing oral dosage form without the pharmaceutically acceptable carrier.
1. A method for replacement therapy in males having a condition or a symptom associated with a deficiency or absence of endogenous testosterone, said method comprising orally administering, with food having 10 to 50 grams of fat, to males having a condition associated with a deficiency or absence of endogenous testosterone twice daily a tablet comprising 100 mg to 400 mg testosterone undecanoate and a pharmaceutically acceptable carrier including at least one of polyvinyl alcohol, polyvinyl pyrrolidones, polyethylene glycols having molecular weight from about 100 to about 20,000; propylene glycol; starches; sodium starch glycolate; croscarmellose; sucrose; lactose; cyclodextrins; carboxymethyl cellulose; microcrystalline cellulose, hydroxyl propyl methyl cellulose; ethyl cellulose; carbomers; gelatin; poloxamers; sodium dodecyl sulfate; sodium docusate; polyoxyethylene sorbitan esters; glycerin; paraffin oil; silicone oils; magnesium aluminosilicates; silicon dioxide; ethyl alcohol; benzyl alcohol; benzyl benzoate; ascorbic acid; or mixtures thereof said method providing a serum testosterone mean Cavg in the range of 400 ng/dL to 600 ng/dL wherein said tablet releases at least 45% of the testosterone undecanoate at 120 minutes and less than 85% of the testosterone undecanoate at 30 minutes when tested, using a USP Type II apparatus, in 1000 mL of 8 wt % Triton X-100 at 37° C. and 100 rpm.
2. The method of claim 1 wherein the tablet is free of lipophilic surfactants.
3. The method of claim 1 wherein the tablet does not form an oil-in-water emulsion when contacted with water with adequate mixing.
4. The method of claim 1 wherein the testosterone undecanoate is present in solid particulate form in the tablet.
5. The method of claim 1 wherein 30% (w/w) or more of the testosterone undecanoate is present in solid particulate form in the tablet.
6. The method of claim 1 wherein the tablet includes 15% or less of lipid substance.
7. A method for replacement therapy in males having a condition associated with a deficiency or absence of endogenous testosterone, said method comprising orally administering, with food having 10 to 50 grams of fat, to males having a condition or a symptom associated with a deficiency or absence of endogenous testosterone twice daily a tablet comprising testosterone undecanoate and a pharmaceutically acceptable carrier including at least one of polyvinyl alcohol, polyvinyl pyrrolidones, polyethylene glycols having molecular weight from about 100 to about 20,000; propylene glycol; starches; sodium starch glycolate; croscarmellose; sucrose; lactose; cyclodextrins; carboxymethyl cellulose; microcrystalline cellulose, hydroxyl propyl methyl cellulose; ethyl cellulose; carbomers; gelatin; poloxamers; sodium dodecyl sulfate; sodium docusate; polyoxyethylene sorbitan esters; glycerin; paraffin oil; silicone oils; magnesium aluminosilicates; silicon dioxide; ethyl alcohol; benzyl alcohol; benzyl benzoate; ascorbic acid; or mixtures thereof, wherein testosterone undecanoate is at least 30% (w/w) solid particulate testosterone undecanoate said method providing a serum testosterone mean Cavg in the range of 400 ng/dL to 600 ng/dL wherein said tablet releases at least 45% of the testosterone undecanoate at 120 minutes and less than 85% of the testosterone undecanoate at 30 minutes when tested, using a USP Type II apparatus, in 1000 mL of 8 wt % Triton X-100 at 37° C. and 100 rpm.
8. The method of claim 7 wherein the tablet is free of lipophilic surfactants.
9. The method of claim 7 wherein the tablet does not form an oil-in-water emulsion when contacted with water with adequate mixing.
10. The method of claim 7 wherein the testosterone undecanoate is present in solid particulate form in the tablet.
11. The method of claim 7 wherein 70% (w/w) or more of the testosterone undecanoate is present in solid particulate form in solid particulate form.
12. The method of claim 7 wherein the tablet includes 15% or less of lipid substance.
13. The method of claim 7 wherein the tablet has from about 100 mg to about 400 mg testosterone undecanoate.
14. A method for replacement therapy in males having a condition or a symptom associated with a deficiency or absence of endogenous testosterone, said method comprising orally administering, with food having 10 to 50 grams of fat, to males having a condition associated with a deficiency or absence of endogenous testosterone twice daily a tablet comprising testosterone undecanoate and a pharmaceutically acceptable carrier including at least one of polyvinyl alcohol, polyvinyl pyrrolidones, polyethylene glycols having molecular weight from about 100 to about 20,000; propylene glycol; starches; sodium starch glycolate; croscarmellose; sucrose; lactose; cyclodextrins; carboxymethyl cellulose; microcrystalline cellulose, hydroxyl propyl methyl cellulose; ethyl cellulose; carbomers; gelatin; poloxamers; sodium dodecyl sulfate; sodium docusate; polyoxyethylene sorbitan esters; glycerin; paraffin oil; silicone oils; magnesium aluminosilicates; silicon dioxide; ethyl alcohol; benzyl alcohol; benzyl benzoate; ascorbic acid; or mixtures thereof wherein said tablet comprises 100 mg to 400 mg of testosterone undecanoate and said method providing a mean Cavg in the range of 400 ng/dL to 600 ng/dL, wherein said tablet releases at least 45% of the testosterone undecanoate at 120 minutes and less than 85% of the testosterone undecanoate at 30 minutes when tested, using a USP Type II apparatus, in 1000 mL of 8 wt % Triton X-100 at 37° C. and 100 rpm.
15. The method of claim 14 wherein the tablet includes 15% or less of lipid substance.
16. The method of claim 14 wherein 30% (w/w) or more of the testosterone undecanoate is present in solid particulate form in the tablet.
17. The method of claim 14 wherein the tablet does not form an oil-in-water emulsion when contacted with water with adequate mixing.
18. The method of claim 7 wherein the tablet has an amount of testosterone undecanoate to pharmaceutically acceptable carrier ratio of from about 2:1 (w/w) to about 1:2 (w/w).
19. The method of claim 1 wherein the testosterone undecanoate is micronized or has a mean particle diameter of 50 μm or less.
20. The method of claim 7 wherein the testosterone undecanoate is micronized or has a mean particle diameter of 50 μm or less.
21. The method of claim 14 wherein the testosterone undecanoate is micronized or has a mean particle diameter of 50 μm or less.